ArticlePregnancy (Hoboken, N.J.)2026
Society for Maternal-Fetal Medicine Statement: Evaluation and management of cell-free DNA screening for fetal red cell antigen genotype in alloimmunized and non-alloimmunized pregnancies.
Article in Pregnancy (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A substantial portion of RhD-negative pregnant patients carry an RhD-negative fetus and are not at risk of RhD alloimmunization. Knowing the fetal RhD genotype allows such patients to avoid unnecessary monitoring or treatment. The use of cell-free DNA (cfDNA) to detect the fetal RhD genotype from maternal blood has been proposed to identify pregnancies in alloimmunized patients at risk for hemolytic disease of the fetus and newborn and to decrease the antenatal use of Rho(D) immune globulin (RhIg) in patients not at risk. However, a number of factors limit the utility of cfDNA for RhD genotyping, including a lack of data that adequately reflect US populations or US laboratory testing approaches and a lack of data or research from independent sources. This document describes considerations and offers guidance on cfDNA screening for red blood cell antigen genotypes in three scenarios: RhD in a non-alloimmunized patient, RhD in a non-alloimmunized patient in the setting of an RhIg shortage, and any fetal red cell antigen genotype in an alloimmunized obstetrical patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.